International AIDS Vaccine Initiative

New York City, New York, United States

International AIDS Vaccine Initiative

New York City, New York, United States
SEARCH FILTERS
Time filter
Source Type

Patent
International Aids Vaccine Initiative | Date: 2017-01-27

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines as well as the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.


Patent
International Aids Vaccine Initiative | Date: 2017-04-05

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.


Patent
International Aids Vaccine Initiative | Date: 2016-09-29

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.


Patent
Theraclone Sciences, Scripps Research Institute and International Aids Vaccine Initiative | Date: 2017-06-14

The specification shows a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also shown. Furthermore, methods for vaccination using suitable epitopes are shown. More specifically, the invention relates to a broadly neutralizing antibody (bNAb) comprising the polypeptide 4869-K15 (PGT-133), i.e to a monoclonal anti-HIV antibody comprising a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 420 and a light chain sequence comprising the amino acid sequence SEQ ID NO: 429.


Patent
Theraclone Sciences, Scripps Research Institute and International Aids Vaccine Initiative | Date: 2016-05-12

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.


Patent
International Aids Vaccine Initiative | Date: 2016-01-12

The present invention relates to novel canine distemper virus (CDV) neutralization-resistant mutants, methods for making the same and uses for vaccine production.


Patent
International Aids Vaccine Initiative | Date: 2016-04-20

The present invention relates to methods of developing gene inserts that are more compatible with the host vectors by modifying a protein sequence to lessen potential interference with vector propagation while ensuring that the protein is expressed and processed efficiently and maintains desired structural features, and designing a gene with a nucleotide sequence that resembles the base composition of the host vector genome.


Patent
International Aids Vaccine Initiative, Scripps Research Institute and The United States Of America | Date: 2016-04-19

The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.


Patent
International Aids Vaccine Initiative and Scripps Research Institute | Date: 2016-03-21

The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.


Patent
International Aids Vaccine Initiative and Scripps Research Institute | Date: 2016-03-21

The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

Loading International AIDS Vaccine Initiative collaborators
Loading International AIDS Vaccine Initiative collaborators